Lanthanide Containing ZnS Nanoparticles

含有 ZnS 纳米粒子的镧系元素

基本信息

  • 批准号:
    7573743
  • 负责人:
  • 金额:
    $ 21.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-06-01 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal describes a program to develop nanoparticles with advanced luminescence properties by combining zinc sulfide (ZnS) semiconductor nanoparticles and luminescent lanthanide cations so that the photophysical advantages of each are exploited. The aim is to use ZnS nanoparticles, with their large absorption cross section, to sensitize the lanthanide cations emission by an "antenna effect" and to provide a matrix that protects the lanthanides from nonradiative deactivation. ZnS is a desirable matrix because it is less toxic than the widely used CdSe nanocrystals, however the ZnS bandgap lies in the ultraviolet/blue spectral region, which has made them incompatible with biological imaging applications because of the strong interference between UV/blue photons and biological systems. However, the addition of lanthanide cations to the ZnS matrix causes the excitation energy to be released through the lanthanide cations as sharp emission bands in the visible and near infrared, determined by the nature of the lanthanide action. The lanthanide cations have sharp well defined emission bands that are insensitive to their environment (such as temperature, pH, pressure or biological environment) and allows for spectral discrimination from biological background (autofluorescence). Lanthanide cations also have longer luminescent lifetimes (micro- to milliseconds) than many other fluorescence emitters, allowing for temporal discrimination between the analyte signal and the background fluorescence. Chemical derivatization of the nanoparticle surface will be used to provide the biochemical selectivity for the nanocrystal probe and to make the material safe and soluble for the targeted biological applications. These materials will be tested in tissue and cell-based preparations and compared to commercially available probes for use in fluorescence microscopy applications. The toxicity of the nanocrystals will be evaluated using highly sensitive optical imaging methodologies for detecting cellular damage and death in primary cell culture models. PUBLIC HEALTH RELEVANCE: We will develop a novel family of luminescent nanoparticles that emit visible or near infrared light and are specifically designed to operate as fluorescent reporters in a broad range of "in vivo" and "in vitro" bioanalytical applications, including biological imaging. Ultimately, these nanoparticles will constitute a versatile luminescence platform whose optical properties will complement existing fluorophores, their signal being easily discriminated from the native fluorescence of biological systems.
描述(由申请人提供):该提案描述了一个程序,通过将硫化锌(ZNS)半导体纳米颗粒和发光灯笼阳离子结合使用,以开发具有晚期发光特性的纳米颗粒。目的是使用具有较大吸收横截面的ZnS纳米颗粒来通过“天线效应”来敏感灯笼阳离子阳离子的发射,并提供一个保护灯笼的矩阵,以保护灯笼剂免受非辐射式失活。 ZnS是一个理想的矩阵,因为它的毒性比广泛使用的CDSE纳米晶体的毒性小,但是ZnS带隙位于紫外线/蓝色光谱区域,这使其与生物成像应用不相容,因为UV/蓝色光子和生物学系统之间的强烈干扰。然而,向ZnS基质中添加灯笼阳离子会导致通过灯笼阳离子释放激发能,作为可见的和接近红外的尖锐发射带,由兰烷基作用的性质确定。灯笼阳离子具有鲜明定义的发射带,对环境不敏感(例如温度,pH,压力或生物环境),并允许从生物背景(自动荧光)中辨别光谱。与许多其他荧光发射器相比,灯笼阳离子的发光寿命(微秒至毫秒)更长,可以在分析物信号和背景荧光之间进行时间歧视。纳米颗粒表面的化学衍生化将用于为纳米晶探针提供生化选择性,并使材料安全可溶于靶向生物学应用。这些材料将在组织和基于细胞的制剂中进行测试,并将其与用于荧光显微镜应用的市售探针进行比较。将使用高度敏感的光学成像方法来评估纳米晶体的毒性,以检测原代细胞培养模型中的细胞损伤和死亡。 公共卫生相关性:我们将开发一个新型的发光纳米颗粒系列,它们发出可见或近红外光,并专门设计为在广泛的“体内”和“体外”生物分析应用中以荧光记者的作用,包括生物学成像。最终,这些纳米颗粒将构成一个多功能发光平台,其光学特性将补充现有的荧光团,它们的信号很容易与生物系统的天然荧光区分开。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID H WALDECK其他文献

DAVID H WALDECK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID H WALDECK', 18)}}的其他基金

Development of Nanoscale Plasmonic Devices for Creation of a Next Generation Surf
开发纳米级等离激元器件以创造下一代冲浪
  • 批准号:
    8252113
  • 财政年份:
    2010
  • 资助金额:
    $ 21.59万
  • 项目类别:
Development of Nanoscale Plasmonic Devices for Creation of a Next Generation Surf
开发纳米级等离激元器件以创造下一代冲浪
  • 批准号:
    8071591
  • 财政年份:
    2010
  • 资助金额:
    $ 21.59万
  • 项目类别:
Development of Nanoscale Plasmonic Devices for Creation of a Next Generation Surf
开发纳米级等离激元器件以创造下一代冲浪
  • 批准号:
    7762447
  • 财政年份:
    2010
  • 资助金额:
    $ 21.59万
  • 项目类别:
Lanthanide Containing ZnS Nanoparticles
含有 ZnS 纳米粒子的镧系元素
  • 批准号:
    7825382
  • 财政年份:
    2009
  • 资助金额:
    $ 21.59万
  • 项目类别:

相似国自然基金

VNN1通过内质网非折叠蛋白应激介导单核巨噬细胞凋亡影响创伤患者脓毒症发生的机制研究
  • 批准号:
    82372549
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
草鱼贮藏过程肌细胞凋亡对鱼肉品质的影响机制研究
  • 批准号:
    32372397
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
MLCK1介导细胞凋亡和自噬影响炎症性肠病进展
  • 批准号:
    82370568
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
EHMT1通过CBX4/MLKL轴调控心肌细胞坏死性凋亡影响心肌缺血再灌注损伤的机制研究
  • 批准号:
    82370288
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
应激颗粒自噬对低氧诱导猪卵泡颗粒细胞凋亡的影响及机制研究
  • 批准号:
    32302741
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

A HUMAN IPSC-BASED ORGANOID PLATFORM FOR STUDYING MATERNAL HYPERGLYCEMIA-INDUCED CONGENITAL HEART DEFECTS
基于人体 IPSC 的类器官平台,用于研究母亲高血糖引起的先天性心脏缺陷
  • 批准号:
    10752276
  • 财政年份:
    2024
  • 资助金额:
    $ 21.59万
  • 项目类别:
Effects of Aging on Neuronal Lysosomal Damage Responses Driven by CMT2B-linked Rab7
衰老对 CMT2B 相关 Rab7 驱动的神经元溶酶体损伤反应的影响
  • 批准号:
    10678789
  • 财政年份:
    2023
  • 资助金额:
    $ 21.59万
  • 项目类别:
The transcriptional control of vascular calcification in disease
疾病中血管钙化的转录控制
  • 批准号:
    10647475
  • 财政年份:
    2023
  • 资助金额:
    $ 21.59万
  • 项目类别:
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy
选择性剪接的细胞表面蛋白作为白血病发生的驱动因素和免疫治疗的靶点
  • 批准号:
    10648346
  • 财政年份:
    2023
  • 资助金额:
    $ 21.59万
  • 项目类别:
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
特发性肺纤维化新型治疗剂的临床前开发
  • 批准号:
    10696538
  • 财政年份:
    2023
  • 资助金额:
    $ 21.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了